Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03796273 · ClinicalTrials.gov registry record · Early Phase 1
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
A Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT03796273 is a Early Phase 1 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 15 participants.
The verdict
NCT03796273, a Early Phase 1 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This trial studies the side effects and how well ketoconazole works before surgery in treating patients with glioma that has come back or breast cancer that has spread to the brain. Ketoconazole is an antifungal drug that may be able to block a protein, tGLI1 and may help to treat brain tumors.
Interventions
- OTHER Best Practice
- DRUG Ketoconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-03-13 |
| Est. Completion | 2022-10-23 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03796273
The ClinicalTrials.gov registry entry for NCT03796273 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Best Practice is the first listed.
NCT03796273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03796273 about?
NCT03796273 is a clinical study titled "Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases". This trial studies the side effects and how well ketoconazole works before surgery in treating patients with glioma that has come back or breast cancer that has spread to the brain. Ketoconazole is an antifungal drug that may be able to block a protein, tGLI1 and may help to treat brain tumors.
What is the current status of trial NCT03796273?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2019-03-13. Estimated completion is 2022-10-23.
What interventions are being tested in trial NCT03796273?
The interventions under investigation include: Best Practice (OTHER), Ketoconazole (DRUG).
Who is sponsoring clinical trial NCT03796273?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.